Medindia

X

Clarient to Present at Upcoming Investment Conferences in New York City

Thursday, September 17, 2009 General News J E 4
Advertisement


ALISO VIEJO, Calif., Sept. 1 Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it is scheduled to make investor presentations at two upcoming investor conferences in New York City.

The first presentation will be made at the Rodman & Renshaw 11th Annual Healthcare Conference at 2:50 pm EDT on Wednesday, September 9. The conference is being held at the New York Palace Hotel.

The second presentation will be made at the Baird 2009 Health Care Conference at 2:15 pm EDT on Thursday, September 10. The conference is being held at the Four Seasons Hotel.

Live webcasts of the presentations will be available via a link provided at http://www.clarientinc.com/investor. Archived replays of the presentations will be available for a period of 90 days from the date of the each presentation.

About Clarient

Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by collaborating with the healthcare community to translate cancer research and development into better patient care. Clarient's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine has created the need for a centralized resource which provides leading oncology diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory, which provides the most advanced oncology testing and diagnostic services available. Resulting diagnostic reports and analyses are made available to customers through Clarient's Internet-based portal, PATHSiTE(TM). Clarient also plans to develop and market new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. www.clarientinc.com

Investor Contact: Matt Clawson Allen & Caron Inc (949) 474-4300 matt@allencaron.com

SOURCE Clarient, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
PreSCD II Registry Shows ICDs Lead to 44 Percent R...
S
Frost & Sullivan Recognizes Carestream Health with...